c-Met binds to and phosphorylates PARP1 in cancer cells, thereby reducing PARP1 binding to a PARP inhibitor; c-Met and PARP inhibitor combination therapy shows improved efficacy in preclinical models of breast and lung cancer.
- Yi Du
- Hirohito Yamaguchi
- Mien-Chie Hung
